Loading
A phase 3 trial of Ceritinib, Pemetrexed and Docetaxel in Non-small-cell lung cancer, run by Novartis Pharmaceuticals, completed.
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib is a phase 3 interventional study registered as NCT01828112 by Novartis Pharmaceuticals, with 231 participants recorded, started 2013-06-28 and reaching its primary completion in 2016-01-26. Interventions recorded: Ceritinib, Pemetrexed, Docetaxel. Conditions recorded: Non-Small Cell Lung Cancer.
Linked to the drug Ceritinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
231 enrolled.
95% CI 4.1 to 6.9; Figures from the ClinicalTrials.gov results section (first posted 2017-07-27), not from a publication · 95% CI 1.4 to 2.8
Source95% CI 14.2 to 23.7; Figures from the ClinicalTrials.gov results section (first posted 2017-07-27), not from a publication · 95% CI 11.9 to 31.2
Source95% CI 31.8 to 50.4; Figures from the ClinicalTrials.gov results section (first posted 2017-07-27), not from a publication · 95% CI 3.0 to 13.1
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC)primary | Ceritinib | 115 | 5.4 months | 0.49 (0.36 to 0.67) | <0.001 | link |
| Chemotherapy | 116 | 1.6 months | ||||
| Overall Survival (OS) | Ceritinib | 115 | 17.7 months | - | - | link |
| Chemotherapy | 116 | 20.1 months | ||||
| Overall Response Rate (ORR) Per BIRC | Ceritinib | 115 | 40.9% | - | - | link |
| Chemotherapy | 116 | 6.9% |
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Docetaxel and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Novartis, Non-small-cell lung cancer and the tag pipeline.